Chemopreventive activity of lantadenes on two-stage carcinogenesis model in Swiss albino mice: AP-1 (c-jun), NFκB (p65) and P53 expression by ELISA and immunohistochemical localization

Molecular and Cellular Biochemistry

Volumn 314, Issue 1-2, 2008, Pages 1-8

  Kaur, Jagdeep ^a   Sharma, Manu ^b   Sharma, P D ^b   Bansal, M P ^a  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Lantadenes; Squamous cell carcinoma; Transcription factors

Indexed keywords

4 O METHYLPHORBOL 13 ACETATE 12 MYRISTATE; ANTINEOPLASTIC AGENT; DIMETHYLBENZ[A]ANTHRACENE; LANTADENE A; LANTADENE A METHYL ESTER; PROTEIN C JUN; PROTEIN P53; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; CYTOPROTECTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTERS; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; NF-KAPPA B; OLEANOLIC ACID; PAPILLOMA; SKIN NEOPLASMS; TISSUE DISTRIBUTION; TRANSCRIPTION FACTOR AP-1; TUMOR SUPPRESSOR PROTEIN P53;

LANTANA CAMARA; MUS;

EID: 42049086093     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-008-9758-9     Document Type: Article

References (37)

1. Parker JN, Zhao W, Askins KJ, Broker TR, Chow LT (1997) Mutational analyses of differentiation-dependent human papillomavirus type 18 enhancer elements in epithelial raft cultures of neonatal foreskin keratinocytes. Cell Growth Differ 8:751-762
2. Holeb AI, Fink DJ, Murphy GP (1991) American cancer society textbook of clinical oncology. Atlana American Cancer Society Inc., pp 456-465
3. Shimada T (2006) Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 21:257-276
4. Siebenlist U, Franzoso G, Brown K (1994) Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10:405-455
5. Angel P, Szabowski A, Schorpp-Kistner M (2001) Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 20:2413-2423
6. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4:131-136
7. Jochum W, Passegué E, Wagner EF (2001) AP-1 in mouse development and tumorigenesis. Oncogene 20:2401-2412
8. Ozanne BW, McGarry L, Spence HJ, Johnston I et al (2000) Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 36:1640-1648
9. Suzuki T, Murakami M, Onai N, Fukuda F et al (1994) Analysis of AP-1 function in cellular transformation pathways. J Virol 68:3527-3535
10. Lamb RF, Hennigan RF, Turnbull K, Katsanakis KD, MacKenzie ED, Birnie GD et al (1997) AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 17:963-976
11. Bone RC, Balk RA, Cerra FB et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies for sepsis. The ACCP/SCCM Conference Committee, American College of Chest Physicians/ Society of Critical Care Medium. Chest 101:1644-1655
12. Ben-Shaul V, Lomintski L, Nyska A, Zurovsky Y, Berman M, Grossman S (2001) The effect of natural antioxidants, NAO and apocynin on oxidative stress in the rat heart following LPS challenge. Toxicol Lett 123:1-10
13. Barnes PJ (1997) Nuclear factor-κB. Int J Biochem Cell Biol 29:867-870
14. Levesque AA, Eastman A (2007) p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor? Carcinogenesis 28:13-20
15. Wattenberg LW (1997) An overview of chemoprevention: Current status and future prospects. Proc Soc Exp Biol Med 216:133-141
16. Singh DK, Lippman SM (1998) Cancer Chemoprevention, Part 1: Retinoids and carotenoids and other classical antioxidants. Oncology (Willison Park) 12:1643-1660
17. Abdullaev GI (2001) Plant derived agent against cancer. In: Gupta SK (ed) Pharmacology and therapeutics in the new millennium, Narosa Publishing House, New Delhi, pp 345-354
18. Kellof GJ, Boone CW, Crowell JA, Steel VE, Luvet R, Sigmen CC (1994) Chemopreventive drug development: Perspectives and progress. Cancer Epidemiol Biomarkers Prev 3:85-98
19. Sharma OP, Vaid J, Sharma PD (1991) Natural products of the lantana plant- the present & prospects. J Sci Ind Res 48:471-478
20. Liu J (1995) Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 40:57-60
21. Sharma M, Sharma PD (2006) Optimization of lantadene isolation & preparation of 22 β-hydroxy oleanolic acid. Chem Nat Comp 42:442-446
22. Inada A, Nakanishi T, Tokuda H, Nishino H, Iwashina A, Sharma OP (1995) Inhibitory effects of Lantadenes & related triterpinoids on Epstein-Barr virus activation. Planta Med 61:558-560
23. Inada A, Nakanishi T, Tokuda T, Nishino H, Iwashina A, Sharma OP (1997) Anti-tumor promoting activities of Lantadenes on mouse skin tumors & mouse hepatic tumors. Planta Med 63:272-274
24. Sharma M, Sharma PD, Bansal MP (2007) Chemopreventive effect of Lantana camara leaf extract on 7,12-Dimethylbenz[a]anthracene-induced squamous cell carcinoma of skin in swiss albino mice. Pharma Biol 45:145-148
25. Azuine MA, Bhide SV (1992) Chemopreventive effect of turmeric against stomach and tumors induced by chemical carcinogenesis in Swiss albino mice. Nutr Cancer 17:77-83
26. Lowry OH, Rosenbrough NJ, Farr AL, Randell RJ (1955) Protein measurement with folin-phenol reagent. J Biol Chem 193:265-275
27. Hess J, Angel P, Schorpp-Kistner M (2004) AP-1 subunits: Quarrel and harmony among siblings. J Cell Sci 117:5965-5973
28. Aggarwal BB, Sethi G, Nair A, Ichikawa H (2006) Nuclear factor-κB: a holy grail in cancer prevention and therapy. Curr Sig Trans Therapy 1:25-52
29. Asehnoune K, Strassheim D, Mitra S, Yeol-Kim M, Abraham E (2004) Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappaB. J Immunol 172:2522-2529
30. Asakura M, Kitakaze M, Takashima S et al (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as new therapy. Nat Med 8:35-40
31. Bharti AC, Donato N, Singh S, Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and I kappa B alpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053-1062
32. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR (1998) The p53 network. J Biol Chem 273:1-4
33. Mowat MR (1998) p53 in tumor progression: Life, death and everything. Adv Cancer Res 74:25-48
34. Arora A, Siddiqui IA, Shuklka Y (2004) Modulation of p53 in 7,12-dimethylbenz[a]anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice. Mol Cancer Ther 3:1459-1466
35. Shin DM, Xu XC, Lippman SM et al (1997) Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 3:875-880
36. Huang H, Ma WY, Goranson A, Dong Z (1999) Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20:237-242
37. She QB, Bode M, Ma WY, Chen NY, Dong Z (2001) Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 61:1604-1610